[{"id":"fffc67bb-7fbb-40b0-9b45-301133ae28bd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04984668","created_at":"2021-07-30T17:55:12.603Z","updated_at":"2024-07-02T16:35:19.910Z","phase":"Phase 1/2","brief_title":"A Phase Ib/II Study of GT90001 Combined With KN046 in Solid Tumors","source_id_and_acronym":"NCT04984668","lead_sponsor":"Suzhou Kintor Pharmaceutical Inc,","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erfonrilimab (KN046) • ascrinvacumab (GT90001)"],"overall_status":"Recruiting","enrollment":" Enrollment 216","initiation":"Initiation: 11/02/2021","start_date":" 11/02/2021","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-02-09"},{"id":"4f4a1258-59e4-47e2-9c5f-489bd6ceb50d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01620970","created_at":"2021-05-14T19:09:31.306Z","updated_at":"2024-07-02T16:36:30.269Z","phase":"Phase 2","brief_title":"PF-03446962 in Relapsed or Refractory Urothelial Cancer","source_id_and_acronym":"NCT01620970","lead_sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","biomarkers":" EGFR • HER-2 • PTEN • KIT • IL6 • FLT1","pipe":"","alterations":" ","tags":["EGFR • HER-2 • PTEN • KIT • IL6 • FLT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ascrinvacumab (GT90001)"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 03/01/2012","start_date":" 03/01/2012","primary_txt":" Primary completion: 06/01/2013","primary_completion_date":" 06/01/2013","study_txt":" Completion: 06/01/2013","study_completion_date":" 06/01/2013","last_update_posted":"2021-05-14"}]